• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures

    New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures

  2. Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies

    Aethlon Medical Announces Receipt of IRB Approval to Initiate Hemopurifier® Clinical Studies

  3. Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NETs1 in the US with Priority Review

    Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NETs1 in the US with Priority Review

  4. Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe

    Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe

  5. Elekta: Elekta’s Versa HD Radiation Therapy System Now Available for Treatment of Cancer Patients in Japan

    Elekta: Elekta’s Versa HD Radiation Therapy System Now Available for Treatment of Cancer Patients in Japan

  6. TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension

    TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension

  7. CorMatrix® Reports FDA Clearance of CorMatrix® CanGaroo™ ECM® Envelope

    CorMatrix® Reports FDA Clearance of CorMatrix® CanGaroo™ ECM® Envelope

  8. QRxPharma: ASX Preliminary Final Report – 2014 Financial Year

    QRxPharma: ASX Preliminary Final Report – 2014 Financial Year

  9. Ocular Therapeutix Announces Second Quarter 2014 Financial Results

    Ocular Therapeutix Announces Second Quarter 2014 Financial Results

  10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In EDAP TMS SA (EDAP) To Contact The Firm

    Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In EDAP TMS SA (EDAP) To Contact The Firm

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.